Polomar Health Services Terminates Merger Agreement with Altanine, Inc.
PMHS sits 44% above its 52-week low of $0.065 on light trading volume (0.4× avg).
Summary
Polomar Health Services announced the termination of its merger agreement with Altanine, Inc., ending a key strategic initiative and adding to the company's existing financial challenges.
Key Events · M&A and Partnerships · PMHS
-
Merger Agreement Terminated
Polomar Health Services and Altanine, Inc. mutually agreed to terminate their merger agreement, effective June 12, 2026. This follows a May 15 filing where critical financial and listing conditions for the merger were waived.
-
Patent License Agreement Terminated
The Know How and Patent License Agreement with Pinata Holdings, Inc., a subsidiary of Altanine, was also terminated. Polomar has until September 7, 2026, to dispose of any remaining inventory or products developed under this agreement.
-
Settlement Payment for Claims
Polomar will pay Altanine $36,000 in three equal installments of $12,000 each, due on June 15, July 15, and August 15, 2026, for the mutual release of 'other claims' between the parties.
Analysis · PMHS · Life Sciences
Polomar Health Services has terminated its merger agreement with Altanine, Inc., a significant strategic reversal for a company already facing substantial financial distress, including a going concern warning and a major lawsuit. This termination removes a potential path for the company's future, especially after conditions for the merger were waived just last month.
At the time of this filing, PMHS was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.07 to $960,000.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.